{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:05:30Z","timestamp":1788998730899,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T00:00:00Z","timestamp":1765065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["CNS2022-135327"],"award-info":[{"award-number":["CNS2022-135327"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FORT23\/00021"],"award-info":[{"award-number":["FORT23\/00021"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-31613-x","type":"journal-article","created":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T05:05:36Z","timestamp":1765083936000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical validation of new alzheimer disease diagnosis tools based on plasma p-Tau217"],"prefix":"10.1038","volume":"16","author":[{"given":"Aleix","family":"Mart\u00ed-Navia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"\u00c1lvarez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ferr\u00e9-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Pe\u00f1a-Bautista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Balaguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevenka","family":"Pedrosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Vico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Baquero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consuelo","family":"Ch\u00e1fer-Peric\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,7]]},"reference":[{"issue":"1","key":"31613_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/13872877241283677","volume":"102","author":"N Beder","year":"2024","unstructured":"Beder, N., Belkhelfa, M. & Leklou, H. Involvement of inflammasomes in the pathogenesis of alzheimer\u2019s disease. J. Alzheimers Dis. 102 (1), 11\u201329. https:\/\/doi.org\/10.1177\/13872877241283677 (2024).","journal-title":"J. Alzheimers Dis."},{"issue":"6","key":"31613_CR2","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/joim.12816","volume":"284","author":"K Blennow","year":"2018","unstructured":"Blennow, K. & Zetterberg, H. Biomarkers for alzheimer\u2019s disease: current status and prospects for the future. J. Intern. Med. 284 (6), 643\u2013663. https:\/\/doi.org\/10.1111\/joim.12816 (2018).","journal-title":"J. Intern. Med."},{"issue":"1","key":"31613_CR3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.cpet.2024.09.015","volume":"20","author":"S Patil","year":"2025","unstructured":"Patil, S. et al. Clinical applications of PET imaging in alzheimer\u2019s disease. PET. Clin. 20 (1), 89\u2013100. https:\/\/doi.org\/10.1016\/j.cpet.2024.09.015 (2025).","journal-title":"PET. Clin."},{"issue":"21","key":"31613_CR4","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.3390\/molecules29215131","volume":"29","author":"AM Thawabteh","year":"2024","unstructured":"Thawabteh, A. M. et al. Recent advances in therapeutics for the treatment of alzheimer\u2019s disease. Molecules 29 (21), 5131. https:\/\/doi.org\/10.3390\/molecules29215131 (2024).","journal-title":"Molecules"},{"issue":"5","key":"31613_CR5","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","volume":"3","author":"O Hansson","year":"2023","unstructured":"Hansson, O., Blennow, K., Zetterberg, H. & Dage, J. Blood biomarkers for alzheimer\u2019s disease in clinical practice and trials. Nat. Aging. 3 (5), 506\u2013519. https:\/\/doi.org\/10.1038\/s43587-023-00403-3 (2023).","journal-title":"Nat. Aging"},{"issue":"11","key":"31613_CR6","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s43587-024-00731-y","volume":"4","author":"J Therriault","year":"2024","unstructured":"Therriault, J. et al. Diagnosis of alzheimer\u2019s disease using plasma biomarkers adjusted to clinical probability. Nat. Aging. 4 (11), 1529\u20131537. https:\/\/doi.org\/10.1038\/s43587-024-00731-y (2024).","journal-title":"Nat. Aging"},{"issue":"3","key":"31613_CR7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton, N. J. et al. Diagnostic accuracy of a plasma phosphorylated Tau 217 immunoassay for alzheimer disease pathology. JAMA Neurol. 81 (3), 255\u2013263. https:\/\/doi.org\/10.1001\/jamaneurol.2023.5319 (2024).","journal-title":"JAMA Neurol."},{"issue":"8","key":"31613_CR8","doi-asserted-by":"publisher","first-page":"5617","DOI":"10.1002\/alz.14073","volume":"20","author":"V Devanarayan","year":"2024","unstructured":"Devanarayan, V. et al. Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early alzheimer\u2019s disease. Alzheimers Dement. 20 (8), 5617\u20135628. https:\/\/doi.org\/10.1002\/alz.14073 (2024).","journal-title":"Alzheimers Dement."},{"issue":"1","key":"31613_CR9","doi-asserted-by":"publisher","first-page":"24519","DOI":"10.1038\/s41598-024-75304-5","volume":"14","author":"JE Galvin","year":"2024","unstructured":"Galvin, J. E., Kleiman, M. J., Estes, P. W., Harris, H. M. & Fung, E. Cognivue clarity characterizes mild cognitive impairment and alzheimer\u2019s disease in biomarker confirmed cohorts in the Bio-Hermes study. Sci. Rep. 14 (1), 24519. https:\/\/doi.org\/10.1038\/s41598-024-75304-5 (2024).","journal-title":"Sci. Rep."},{"key":"31613_CR10","doi-asserted-by":"publisher","unstructured":"\u00c1lvarez-S\u00e1nchez, L. et al. New approach to specific Alzheimer\u2019s disease diagnosis based on plasma biomarkers in a cognitive disorder cohort. Eur. J. Clin. Invest. e70034 https:\/\/doi.org\/10.1111\/eci.70034 (2025).","DOI":"10.1111\/eci.70034"},{"issue":"10","key":"31613_CR11","doi-asserted-by":"publisher","first-page":"7281","DOI":"10.1002\/alz.14215","volume":"20","author":"T Xu","year":"2024","unstructured":"Xu, T. et al. Genetic spectrum features and diagnostic accuracy of four plasma biomarkers in 248 Chinese patients with frontotemporal dementia. Alzheimers Dement. 20 (10), 7281\u20137295. https:\/\/doi.org\/10.1002\/alz.14215 (2024).","journal-title":"Alzheimers Dement."},{"key":"31613_CR12","doi-asserted-by":"publisher","unstructured":"Yilmaz, S. N. et al. From Organotypic Mouse Brain Slices to Human Alzheimer\u2019s Plasma Biomarkers: A Focus on Nerve Fiber Outgrowth. Biomolecules. 14(10), 1326. Published. Oct 18. (2024). https:\/\/doi.org\/10.3390\/biom14101326 (2024).","DOI":"10.3390\/biom14101326"},{"key":"31613_CR13","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-4947448\/v1","author":"T Karikari","year":"2024","unstructured":"Karikari, T. et al. A streamlined, resource-efficient immunoprecipitation-mass spectrometry method for quantifying plasma amyloid-\u03b2 biomarkers in alzheimer\u2019s disease. Res. Sq. https:\/\/doi.org\/10.21203\/rs.3.rs-4947448\/v1 (2024). rs.3.rs-4947448.","journal-title":"Res. Sq"},{"issue":"18","key":"31613_CR14","doi-asserted-by":"publisher","first-page":"14151","DOI":"10.3390\/ijms241814151","volume":"24","author":"L \u00c1lvarez-S\u00e1nchez","year":"2023","unstructured":"\u00c1lvarez-S\u00e1nchez, L. et al. Early alzheimer\u2019s disease screening approach using plasma biomarkers. Int. J. Mol. Sci. 24 (18), 14151. https:\/\/doi.org\/10.3390\/ijms241814151 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"31613_CR15","doi-asserted-by":"publisher","first-page":"e0022","DOI":"10.1016\/j.plabm.2021.e00220","volume":"25","author":"M Lotierzo","year":"2021","unstructured":"Lotierzo, M., Urbain, V., Dupuy, A. M. & Cristol, J. P. Evaluation of a new automated immunoassay for the quantification of anti-M\u00fcllerian hormone. Pract. Lab. Med. 25, e0022. https:\/\/doi.org\/10.1016\/j.plabm.2021.e00220 (2021).","journal-title":"Pract. Lab. Med."},{"issue":"4","key":"31613_CR16","doi-asserted-by":"publisher","first-page":"188","DOI":"10.12779\/dnd.2024.23.4.188","volume":"23","author":"HS Kwon","year":"2024","unstructured":"Kwon, H. S., Yu, H. J. & Koh, S. H. Revolutionizing alzheimer\u2019s diagnosis and management: the dawn of Biomarker-Based precision medicine. Dement. Neurocogn Disord. 23 (4), 188\u2013201. https:\/\/doi.org\/10.12779\/dnd.2024.23.4.188 (2024).","journal-title":"Dement. Neurocogn Disord"},{"issue":"6","key":"31613_CR17","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1515\/cclm-2023-1434","volume":"62","author":"B Arslan","year":"2024","unstructured":"Arslan, B., Zetterberg, H. & Ashton, N. J. Blood-based biomarkers in alzheimer\u2019s disease - moving towards a new era of diagnostics. Clin. Chem. Lab. Med. 62 (6), 1063\u20131069. https:\/\/doi.org\/10.1515\/cclm-2023-1434 (2024).","journal-title":"Clin. Chem. Lab. Med."},{"key":"31613_CR18","doi-asserted-by":"publisher","first-page":"105405","DOI":"10.1016\/j.ebiom.2024.105405","volume":"109","author":"A Feizpour","year":"2024","unstructured":"Feizpour, A. et al. Detection and staging of alzheimer\u2019s disease by plasma pTau217 on a high throughput immunoassay platform. EBioMedicine 109, 105405. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105405 (2024).","journal-title":"EBioMedicine"},{"issue":"1","key":"31613_CR19","doi-asserted-by":"publisher","first-page":"16316","DOI":"10.1038\/s41598-025-01511-3","volume":"15","author":"L \u00c1lvarez-S\u00e1nchez","year":"2025","unstructured":"\u00c1lvarez-S\u00e1nchez, L. et al. Promising clinical tools for specific alzheimer disease diagnosis from plasma pTau217 and ApoE genotype in a cognitive disorder unit. Sci. Rep. 15 (1), 16316. https:\/\/doi.org\/10.1038\/s41598-025-01511-3 (2025).","journal-title":"Sci. Rep."},{"key":"31613_CR20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.neurobiolaging.2024.08.007","volume":"143","author":"V Quaresima","year":"2024","unstructured":"Quaresima, V. et al. Plasma p-tau181 and amyloid markers in alzheimer\u2019s disease: A comparison between lumipulse and SIMOA. Neurobiol. Aging. 143, 30\u201340. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2024.08.007 (2024).","journal-title":"Neurobiol. Aging"},{"issue":"6","key":"31613_CR21","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.14283\/jpad.2024.152","volume":"11","author":"F Mart\u00ednez-Dubarbie","year":"2024","unstructured":"Mart\u00ednez-Dubarbie, F. et al. Diagnostic accuracy of plasma p-tau217 for detecting pathological cerebrospinal fluid changes in cognitively unimpaired subjects using the lumipulse platform. J. Prev. Alzheimers Dis. 11 (6), 1581\u20131591. https:\/\/doi.org\/10.14283\/jpad.2024.152 (2024).","journal-title":"J. Prev. Alzheimers Dis."},{"issue":"5","key":"31613_CR22","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.14283\/jpad.2024.110","volume":"11","author":"M Manjavong","year":"2024","unstructured":"Manjavong, M. et al. Performance of plasma biomarkers combined with structural MRI to identify candidate participants for alzheimer\u2019s Disease-Modifying therapy. J. Prev. Alzheimers Dis. 11 (5), 1198\u20131205. https:\/\/doi.org\/10.14283\/jpad.2024.110 (2024).","journal-title":"J. Prev. Alzheimers Dis."},{"issue":"11","key":"31613_CR23","doi-asserted-by":"publisher","first-page":"7913","DOI":"10.1002\/alz.14280","volume":"20","author":"K Dhana","year":"2024","unstructured":"Dhana, K. et al. External validation of dementia prediction models in black or African American and white older adults: A longitudinal population-based study in the united States. Alzheimers Dement. 20 (11), 7913\u20137922. https:\/\/doi.org\/10.1002\/alz.14280 (2024).","journal-title":"Alzheimers Dement."},{"key":"31613_CR24","doi-asserted-by":"publisher","unstructured":"Warmenhoven, N. et al. A Comprehensive Head-to-Head Comparison of Key Plasma Phosphorylated Tau 217 Biomarker Tests. Preprint. medRxiv; (2024). https:\/\/doi.org\/10.1101\/2024.07.02.24309629","DOI":"10.1101\/2024.07.02.24309629"},{"issue":"9","key":"31613_CR25","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","volume":"3","author":"WS Brum","year":"2023","unstructured":"Brum, W. S. et al. A two-step workflow based on plasma p-tau217 to screen for amyloid \u03b2 positivity with further confirmatory testing only in uncertain cases. Nat. Aging. 3 (9), 1079\u20131090. https:\/\/doi.org\/10.1038\/s43587-023-00471-5 (2023).","journal-title":"Nat. Aging"},{"issue":"9","key":"31613_CR26","doi-asserted-by":"publisher","first-page":"e70051","DOI":"10.1111\/cns.70051","volume":"30","author":"TR Li","year":"2024","unstructured":"Li, T. R. et al. A prediction model of dementia conversion for mild cognitive impairment by combining plasma pTau181 and structural imaging features. CNS Neurosci. Ther. 30 (9), e70051. https:\/\/doi.org\/10.1111\/cns.70051 (2024).","journal-title":"CNS Neurosci. Ther."},{"issue":"1","key":"31613_CR27","doi-asserted-by":"publisher","first-page":"17557","DOI":"10.1038\/s41598-024-66195-7","volume":"14","author":"W Li","year":"2024","unstructured":"Li, W., Sun, L., Yue, L. & Xiao, S. Diagnostic and predictive power of plasma proteins in alzheimer\u2019s disease: a cross-sectional and longitudinal study in China. Sci. Rep. 14 (1), 17557. https:\/\/doi.org\/10.1038\/s41598-024-66195-7 (2024).","journal-title":"Sci. Rep."},{"key":"31613_CR28","doi-asserted-by":"publisher","first-page":"118996","DOI":"10.1016\/j.cca.2024.118996","volume":"558","author":"S Torres Robledillo","year":"2024","unstructured":"Torres Robledillo, S. et al. Validation of plasma biomarkers in alzheimer disease. Clin. Chim. Acta. 558, 118996 (2024). 1016\/j.cca.2024.118996.","journal-title":"Clin. Chim. Acta"},{"issue":"4","key":"31613_CR29","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.14283\/jpad.2024.58","volume":"11","author":"GM Giuffr\u00e8","year":"2024","unstructured":"Giuffr\u00e8, G. M. et al. Performance of fully-automated high-throughput plasma biomarker assays for alzheimer\u2019s disease in amnestic mild cognitive impairment subjects. J. Prev. Alzheimers Dis. 11 (4), 1073\u20131078. https:\/\/doi.org\/10.14283\/jpad.2024.58 (2024).","journal-title":"J. Prev. Alzheimers Dis."},{"issue":"1","key":"31613_CR30","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/acn3.51695","volume":"10","author":"TF Tropea","year":"2023","unstructured":"Tropea, T. F. et al. Plasma phosphorylated tau181 predicts cognitive and functional decline. Ann. Clin. Transl Neurol. 10 (1), 18\u201331. https:\/\/doi.org\/10.1002\/acn3.51695 (2023).","journal-title":"Ann. Clin. Transl Neurol."},{"key":"31613_CR31","doi-asserted-by":"publisher","unstructured":"Arranz, J. et al. Diagnostic performance of plasma pTau 217, pTau 181, A\u03b2 1\u201342 and A\u03b2 1\u201340 in the LUMIPULSE automated platform for the detection of alzheimer disease. Preprint Res. Sq. rs.3.rs-3725688 https:\/\/doi.org\/10.21203\/rs.3.rs-3725688\/v1 (2023).","DOI":"10.21203\/rs.3.rs-3725688\/v1"},{"issue":"4","key":"31613_CR32","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","volume":"30","author":"NR Barth\u00e9lemy","year":"2024","unstructured":"Barth\u00e9lemy, N. R. et al. Highly accurate blood test for alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests. Nat. Med. 30 (4), 1085\u20131095. https:\/\/doi.org\/10.1038\/s41591-024-02869-z (2024).","journal-title":"Nat. Med."},{"issue":"16","key":"31613_CR33","doi-asserted-by":"publisher","first-page":"4735","DOI":"10.3390\/jcm13164735","volume":"13","author":"M Baquero","year":"2024","unstructured":"Baquero, M. et al. Insights from a 7-Year dementia cohort (VALCODIS): ApoE genotype evaluation. J. Clin. Med. 13 (16), 4735. https:\/\/doi.org\/10.3390\/jcm13164735 (2024).","journal-title":"J. Clin. Med."},{"issue":"4","key":"31613_CR34","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack, C. R. Jr. et al. NIA-AA research framework: toward a biological definition of alzheimer\u2019s disease. Alzheimers Dement. 14 (4), 535\u2013562. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018 (2018).","journal-title":"Alzheimers Dement."},{"issue":"11","key":"31613_CR35","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","volume":"14","author":"O Hansson","year":"2018","unstructured":"Hansson, O. et al. CSF biomarkers of alzheimer\u2019s disease concord with amyloid-\u03b2 PET and predict clinical progression: A study of fully automated immunoassays in biofinder and ADNI cohorts. Alzheimers Dement. 14 (11), 1470\u20131481. https:\/\/doi.org\/10.1016\/j.jalz.2018.01.010 (2018).","journal-title":"Alzheimers Dement."},{"issue":"7","key":"31613_CR36","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1002\/alz.12897","volume":"19","author":"A Leuzy","year":"2023","unstructured":"Leuzy, A. et al. Robustness of CSF A\u03b242\/40 and A\u03b242\/P-tau181 measured using fully automated immunoassays to detect AD-related outcomes. Alzheimers Dement. 19 (7), 2994\u20133004. https:\/\/doi.org\/10.1002\/alz.12897 (2023).","journal-title":"Alzheimers Dement."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31613-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31613-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31613-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T19:04:08Z","timestamp":1768331048000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31613-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,7]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["31613"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-31613-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,7]]},"assertion":[{"value":"3 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Committee from Instituto de Investigaci\u00f3n Sanitaria La Fe (Valencia, Spain) (Reference number: 2022-990-1).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"All participants signed informed consent prior to their recruitment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"1472"}}